JournalTOCs

Cancer and Clinical Oncology
Number of Followers: 9

This is an Open Access Journal

Open Access journal
ISSN (Print) 1927-4858 - ISSN (Online) 1927-4866
Published by CCSE

[43 journals]

The Changes of Expression Levels in Mir-181a and Mir-30d, and a
Significant Correlation between Clinical Patient Data
- Abstract: Purpose: Colorectal cancer is known as the most common gastrointestinal cancers. As the age increases, the risk for this cancer also increases, so the only way to improve and hope for life in these patients is early diagnosis of the disease. So far, numerous molecular studies have been carried out on microRNAs in colorectal cancer. In addition, since some of them can be identified as cancer biomarkers. Therefore, in this study we have investigated the expression level of Mir-30d and Mir-181a as cancer biomarkers.Method: The changes of Mir-30d and Mir-181a expression levels in 60 colorectal tumor tissues and 60 adjacent tumor tissues, after RNA extraction and cDNA synthesis were surveyed using the Real Time-PCR method.Results: The results have reported a considerable reduction in the expression level of Mir-30d in tumor tissues, as well as a significant increase in the expression level of Mir-181a tumor expression in tumor tissues (P
  PubDate: Sat, 02 Nov 2019 02:39:54 +000
Reviewer Acknowledgements for Cancer and Clinical Oncology, Vol. 8, No. 1
- Abstract: Cancer and Clinical Oncology wishes to acknowledge the following individuals for their assistance with peer review of manuscripts for this issue. Their help and contributions in maintaining the quality of the journal is greatly appreciated.Cancer and Clinical Oncology is recruiting reviewers for the journal. If you are interested in becoming a reviewer, we welcome you to join us. Please find the application form and details at http://www.ccsenet.org/reviewer and e-mail the completed application form to cco@ccsenet.org. Reviewers for Volume 8, Number 1Aditya R Bele, University of Florida, USAAnand Kumar, Banaras Hindu University, IndiaBehjatolah Monzavi-Karbassi, University of Arkansas for Medical Sciences, USAHua Wang, Memorial Sloan Kettering Cancer Center, ChinaJulita Kulbacka, Wroclaw Medical University, PolandKartik Anand, Houston Methodist Cancer Center, USAMaral Mazloumi Tabrizi, Islamic Azad University, IranPremila Leiphrakpam, University of Nebraska Medical Center, USAVignesh Viswanathan, Stanford University, USA
  PubDate: Fri, 28 Jun 2019 03:15:44 +000
Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal
Cancer
- Abstract: Treatment of metastatic colorectal cancer (mCRC) is one of the most challenging and important problems in oncology at present moment. This article presents the interim results of treatment of patients with colorectal cancer, who were enrolled from 2016 till 2019 (n=60) with the use of maintenance metronomic chemotherapy. Metronomic regimen consisted of oral capecitabine 500 mg 3 times a day and oral cyclophosphane 50 mg daily. The control arm consisted of mCRC patients who received the same induction chemotherapy without maintenance from 2011 till 2015 (n=70). Median follow-up time was 18.5 months. Median progression-free survival (PFS) was 9.0 and 7.4 months in the maintenance and control arms respectively. Median overall survival (OS), counted from the beginning of induction chemotherapy, is currently 22.9 months in the maintenance arm, and 14.7 months in control. High expression levels of genes, encoding enzymes TS (thymidylate synthetase), DPD (dihydropyrimidine dehydrogenase) and receptor VEGFR1, low expression level of gene TP (thymidylate phosphorylase), as well as low levels of tumor markers CEA and СА 19-9 are the prognostic factors of sensitivity to metronomic chemotherapy given to colorectal cancer patients. Based on these data, we identified a group of patients who are recommended to use this method of treatment.
  PubDate: Fri, 28 Jun 2019 03:09:18 +000
Personal Loss and Grief Experiences of Healthcare Personnel in Pre- and
Perinatal Care: A Review of Literature
- Abstract: Pre- and perinatal loss and grief tend to be referred to as complicated grief denoting the experience of ongoing trauma. It is considered a burden for the affected parents, their families and the helping professionals alike. Yet this phenomenon remains an underrepresented field in analytical studies. Our aim is to systematically review the literature that deals with personal grief caused by pre- and perinatal loss - as experienced by healthcare staff. We shall present a comprehensive view of relevant international and national attitudes including existing grief management options. The above-mentioned complex issue deserves greater attention, which should result in the establishment of dynamic, up-to-date support programmes on all professional levels.
  PubDate: Thu, 20 Jun 2019 02:12:20 +000
Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston
AS2-1 in Combination with Targeted Therapy
- Abstract: Treatment of recurrent glioblastoma multiforme (rGBM) poses a difficult challenge. Therefore, the purpose of this report was to evaluate objective response (OR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs) in rGBM patients, age 19-70 years, who were treated with antineoplaston AS2-1 (Astugenal) plus targeted therapy. A retrospective analysis was performed. Tumor response was assessed by gadolinium-enhanced magnetic resonance imaging (MRI). Twenty-nine adult rGBM patients were treated between 9/11/2015 and 06/23/2018. Seven had no prior treatment with bevacizumab elsewhere, had radiologic evidence of rGBM, and had MRI assessment of tumor response. The median treatment time was 101 days (range: 55-208 days). OR was seen in six patients (85.7%) with complete disappearance of gadolinium enhancement in four patients (57.1%) and a 50% or greater reduction in gadolinium enhancement in two patients (28.6%). Progressive disease was seen in one patient (14.3%). The median time to first response was 29 days (range: 22-96 days) while the median duration of response was 141 days (range 55-739+ days). Six- and 12-month PFS was 57% and 19%, respectively while 6- and 12-month OS at was 86% and 54%, respectively. Treatment was well-tolerated with no patients experiencing grade 3 or 4 antineoplaston-related toxicity. Regarding response to treatment and toxicity, AS2-1 plus targeted therapy compares favorably with other reported rGBM therapies. Duration of response was shortened by the ill-advised decision of some patients to discontinue treatment after a tumor response was achieved.
  
  PubDate: Tue, 29 Jan 2019 05:26:00 +000

HOME > Browse the 3359 Publishers covered by JournalTOCs	1 2 3 4 5 6 7 8
Publisher	Total Journals
	1 2 3 4 5 6 7 8